 Economic Times | Pipeline Setback at Abbott - Analyst Blog NASDAQ Other late-stage candidates at Abbott Labs includes levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson's disease and daclizumab for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs has partnered with Biogen Idec ... Abbott Laboratories Management Discusses Q3 2012 Results - Earnings Call ... EPS Beat for Abbott, Sales Miss |
